CA
GLUE icon

Cliff Asness’s Monte Rosa Therapeutics GLUE Stock Holding History

Cliff Asness’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Sell
520,648
-137,835
-21% -$2.6M ﹤0.01% 1425
2026
Q1 		$10.8M Sell
658,483
-126,574
-16% -$2.42M 0.01% 1303
2025
Q4 		$12.3M Buy
785,057
+67,795
+9% +$914K 0.01% 1120
2025
Q3 		$5.31M Sell
717,262
-566,680
-44% -$3M ﹤0.01% 1421
2025
Q2 		$5.79M Buy
1,283,942
+1,054,406
+459% +$4.7M ﹤0.01% 1202
2025
Q1 		$1.07M Buy
+229,536
New +$1.41M ﹤0.01% 1978

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cliff Asness's GLUE Position: Q2 2026 in Review

Cliff Asness reduced its Monte Rosa Therapeutics (GLUE) stake by 21% in Q2 2026, selling an estimated $2.6M and leaving 520,648 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1425.

Cliff Asness first reported a position in GLUE in Q1 2025 and has held it in 6 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Cliff Asness held 520,648 shares of Monte Rosa Therapeutics worth $12.6M as of Q2 2026.
  • Cliff Asness sold 137,835 Monte Rosa Therapeutics shares in Q2 2026, an estimated $2.6M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #1425 holding.
  • Cliff Asness first reported a position in Monte Rosa Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.